The collaboration, which is aligned with the Russian Government initiative, is aimed at building new pharmaceutical industry and widening therapeutic opportunities for the patients in Russia.
CDRI chairman Nikolay Savchuk said CDRI is actively involved in both developing new molecules and improving existing drugs, covering the full cycle from pre-clinical development through manufacturing.
"Our collaboration with global healthcare leader Abbott will draw on the company’s expertise and technologies and Russia’s significant scientific potential to effectively develop new products of the highest quality based on existing drugs," Savchuk added.
Initially the collaboration will focus on creating advanced forms of the existing Abbott’s pharmaceutical products by developing new technologies.
The partnership also includes other ongoing discussions between the parties regarding programs for joint small molecule medicine’s development and enhancement.
Intellectual Dialog, ChemRar’s R&D company, also launched a research project with Abbott aimed at prevention and treatment of selected viral diseases impacting children and the elderly.